|
|
|||
|
|||
|
|
|||
|
accolate allergies |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
accolate allergies DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide accolate allergies. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water accolate allergies. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone accolate allergies. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration accolate allergies. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide accolate allergies.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans accolate allergies. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs accolate allergies. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness accolate allergies. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges accolate allergies. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma accolate allergies. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma accolate allergies. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge accolate allergies. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma accolate allergies. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma accolate allergies. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg accolate allergies. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data accolate allergies. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% accolate allergies. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below accolate allergies. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed accolate allergies. Elderly: The apparent oral clearance of zafirlukast decreases with age accolate allergies. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients accolate allergies. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults accolate allergies. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects accolate allergies. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects accolate allergies. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| aaccolate allergies acccolate allergies acccolate allergies accoolate allergies accollate allergies accolaate allergies accolatte allergies accolatee allergies accolate allergies accolate allergies accolate aallergies accolate alllergies accolate alllergies accolate alleergies accolate allerrgies accolate allerggies accolate allergiies accolate allergiees accolate allergiess ccolate allergies acolate allergies acolate allergies acclate allergies accoate allergies accolte allergies accolae allergies accolat allergies accolate allergies accolate allergies accolate llergies accolate alergies accolate alergies accolate allrgies accolate allegies accolate alleries accolate allerges accolate allergis accolate allergie a ccolate allergies ac colate allergies acc olate allergies acco late allergies accol ate allergies accola te allergies accolat e allergies accolate allergies accolate allergies accolate allergies accolate a llergies accolate al lergies accolate all ergies accolate alle rgies accolate aller gies accolate allerg ies accolate allergi es accolate allergie s accolate allergies cacolate allergies accolate allergies acoclate allergies accloate allergies accoalte allergies accoltae allergies accolaet allergies accolat e allergies accolate allergies accolate a llergies accolate lalergies accolate allergies accolate alelrgies accolate allregies accolate allegries accolate alleriges accolate allergeis accolate allergise aaccolate allergies theaccolate allergies accolate allergies | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
